Atherogenic index of plasma is an independent predictor of ultrasound-proven nonalcoholic fatty liver disease among non-obese populations.

Hua-Jun Ye

Wenzhou Medical University

Xu-Yan Chen

Wenzhou Medical University

Zhi-Ming Huang

wenzhou medical university

XiXi He (✉ wyyhxx@126.com)

Wenzhou Medical University

Research Article

Keywords: NAFLD, incidence, Atherogenic index of plasma

Posted Date: November 22nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-152637/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background & Aims: Evidence regarding the association between atherogenic index of plasma (AIP) and the risk of non-alcoholic fatty liver disease (NAFLD) in non-obese populations is limited. Our study aimed to investigate whether AIP predicts NAFLD in non-obese Chinese populations.

Methods: The present study was a population-based longitudinal study, including 16 173 non-obese participants who underwent health examinations in a tertiary hospital from January 2010 to December 2014. The primary outcome was developing NAFLD during the follow-up period.

Results: The mean age of the included participants was 43.2 ± 15.0 years old, and about 52.5% of them were male. During the follow-up period, 2 322 of 16 173 (14.3%) participants developed NAFLD. In the fully-adjusted model, for every one standard deviation increased in AIP levels, the incidence of NAFLD increased by 52% (1.52, 95%CI 1.43, 1.60). The optimal cut-off point of AIP for incident NAFLD was 0.00 (receiver operator characteristic 0.76 [95% CI 0.75–0.77], sensitivity 0.68, specificity 0.72). Individuals with AIP values in the positive range had two-fold increased odds of developing NAFLD compared with those with values in the negative range. After propensity score matching, for every one-SD increased in AIP levels, the incidence of NAFLD increased by 34% (HR 1.34, 95%CI 1.27, 1.41).

Conclusion: AIP is an independent predictor of incident NAFLD among Chinese non-obese populations.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a complex disorder. The main characteristic is an excessive fat deposition in the hepatocyte induced by pathologic factors absence of alcohol abuse and other known factors that injure the liver[1]. The histopathologic spectrum of NAFLD comprises simple steatosis, nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma[2]. With the rising incidence of obesity, diabetes and metabolic syndrome, nonalcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease worldwide [3, 4].

Atherogenic index of plasma (AIP), a logarithmically transformed ratio of triglycerides (TGs) and high-density lipoprotein cholesterol (HDL-c), is considered an atherogenic indicator independent of other lipids[5]. Dobiasova et al. have reported that AIP was a powerful predictor of coronary atherosclerosis[6]. More and more evidences indicated that AIP may be more closely related to CVD risk than other atherogenic indices[7]. In addition, recent studies have indicated that AIP was a useful tool in predicting the risk of diabetes and mortality[8-10].

Around 10 to 20% of participants develop NAFLD with a relatively normal body mass index (BMI)[11]. Non-obese or lean NAFLD has attracted attention. The evidence of the association between AIP and

incident NAFLD among non-obese participants is limited. Our study aimed to investigate the relationship between AIP and the risk of NAFLD among non-obese Chinese populations.

Methods

Study participants and design

The present study is a longitudinal cohort study. We obtained data from the 'Dryad Digital Repository' website (www.Datadryad.org)^[12]. A sample of 16 173 initially NAFLD-free non-obese individuals, who underwent health examinations in a tertiary hospital from January 2010 to December 2014, was consecutively collected. The study was approved by the Ethics Committee of the local hospital. No informed consent was required because the data are anonymized.

Data collection

We extracted biochemical parameters from the database as follows: alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ -glutamyl transpeptidase (GGT), albumin, bilirubin, blood urea nitrogen (BUN), creatinine, fasting plasma glucose (FPG), uric acid (UA), total cholesterol (TC), TG, HDL-C, and LDL-C. levels. Demographic data were recorded by physicians. Anthropometric data were measured by trained staffs. All laboratory parameters were measured by an automated analyzer (Abbott AxSYM) using standard methods.

Definition

Atherogenic Index of Plasma (AIP) was calculated as $\text{Log}(\text{Triglycerides}/\text{HDL-Cholesterol})$. Non-obese was defined as $\text{BMI} < 25 \text{ kg/m}^2$ ^[13]. Abdominal ultrasonography was performed in a blinded manner to determine the diagnosis of fatty liver (a "bright" liver with increased echogenicity, deep attenuation, and vascular blurring). The diagnosis of NAFLD was based on the guideline of Chinese Society of Hepatology^[14].

Participants were excluded for the following reasons: (1) having fatty liver

disease at baseline examination; (2) excessive alcohol consumption (≥ 140

g/week in men or ≥ 70 g/week in women); (3) presence of viral hepatitis, autoimmune

hepatitis, drug-induced liver injury, or other known chronic liver diseases; (4) obesity ($\text{BMI} \geq 25 \text{ kg/m}^2$); (5) treatment with antidiabetic, hypoglycemic, or lipid-lowering drugs; (6) lost to follow-up; (7) incomplete

clinical or biochemical data.

Follow-up and outcome

Participants received the health examinations every year during the observation period (January 2010-December 2014). The procedures for follow-up evaluation were the same as those used at baseline. The primary outcome was developing NAFLD during the follow-up period.

Statistical analyses

According to the normal or non-normal distribution, continuous variables were expressed as mean $\pm$ standard deviation (SD) or median with interquartile range (IQRs). Categorical variables were expressed as the number (%). Comparisons between the participants groups were made by the chi-square test or the Fisher exact test for categorical variables, and by the unpaired Student t-test, the Mann-Whitney U test, the one-way analysis of variance (ANOVA) or the Kruskal-Wallis test for normally and non-normally distributed continuous variables as appropriate.

To investigate whether AIP is an independent predictor of incident NAFLD in selected participants, we conducted four main statistical methods. Method one: Univariate and multivariate Cox regression model. Method two: Generalized additive model and smooth curve fitting (penalized spline method) to study the shape of the association of AIP levels and the incidence of NAFLD. Method three: Propensity score matching (PSM) was used to compensate for differences in baseline characteristics. Matching was performed with the use of a 1:1 matching protocol, with the propensity score in a range of ± 0.05 . Method four: Stratified and interaction analyses. Continuous variables were transformed to categorical variables according to the clinical cut points. Sensitivity analyses was conducted to ensure the robustness of the results. To maximize statistical power and minimize bias that might occur if individuals with missing data were excluded from analyses, we used multiple imputation, based on 5 replications and a chained equation approach method in the R MI procedure, to account for missing data on ALT, AST, GGT, albumin, and bilirubin. The optimal cut-off point was calculated based on receiver operator characteristic (ROC) analyses. The sensitivity and specificity values at the optimal cut-off point were also calculated.

R (<http://www.R-project.org>, The R Foundation) and MedCalc (version 15.2.2 Ostend, Belgium) were used for statistical analyses. All statistical analyses were two-sided and statistical significance was set at $p < 0.05$.

Results

Baseline characteristics of selected participants

Based on the inclusion and exclusion criteria, a total of 16 173 participants were selected for final data analysis. We showed baseline characteristics of these included participants in **Table 1** stratified by quartile of AIP levels. The mean age of the included participants was 43.2 ± 15.0 years old, and about 52.5% of them were male. Individuals with the higher AIP level had significantly higher levels of age, BMI, SBP, DBP, ALT, AST, GGT, creatinine, UA, FPG, and LDL-C than those with the lower AIP level.

Univariate analysis

Table 2 presented the results of univariate analyses. HDL-c (HR 0.28, 95%CI 0.25-0.32) was negatively associated with incident NAFLD. In contrast, age, BMI, SBP, DBP, ALT, AST, GGT, creatinine, UA, FPG, TG, TC, and LDL-C levels were positively associated with incident NAFLD. **Figure 1** showed the Kaplan-Meier curves illustrating the cumulative incidence of NFALD stratified by different AIP levels. The Log-rank test was used to compare each group with the others, and the incidences were different for each group ($p < 0.001$).

Independent effects of AIP on incident NAFLD

The independent effect of AIP on incident NAFLD was assessed after adjusting for other potential confounders. The effect values (HR) and 95% confidence intervals (CI) were listed in **Table 3**. In the unadjusted model, for every one standard deviation (SD, 0.28) increase in AIP level, the incidence of NAFLD increased by 97% (HR 1.97, 95% CI 1.97, 2.04). In the minimum-adjusted model (model I), for every one-SD increase, the incidence of NAFLD increased by 58% (HR 1.58, 95% CI 1.52, 1.63). In the fully-adjusted model (model II, adjusted all the covariates presented in table 1), for every one-SD increase in AIP level, the incidence of NAFLD increased by 52% (HR 1.52, 95%CI 1.43, 1.60). Consistently, when AIP was assessed as quartiles, compared with the lowest AIP level (Q1 < -0.31), the fully adjusted HR for incident NAFLD in the highest AIP level (Q4 > 0.07) was 4.51 (95%CI 3.40, 5.97). A significantly higher risk of incident NAFLD (HR 1.92, 95%CI 1.72-2.15) was also found in those in the fourth quartile (Q4) compared with participants in the first to third quartiles (Q1-3). **Figure 2** shows the relationship between baseline AIP levels and the incidence of NAFLD before and after fully adjusted.

We further used propensity score matching (PSM) model to assess the association between AIP levels and incident NAFLD (**Table 4**). We matched 1365 participants without NAFLD to 1365 participants with finally diagnosed NAFLD. After matching, age, sex, BMI, SBP, DBP, ALT, AST, GGT, albumin, bilirubin, BUN,

creatinine, UA, FPG, TC, LDL-c, and year of follow-up were similar between two groups (all $p > 0.10$). Participants finally diagnosed NAFLD had higher baseline AIP level than those without NAFLD (per SD, HR 1.34, 95%CI 1.27, 1.41, $p < 0.001$). Although the effect sizes magnitude of the PSM model was slightly different from the fully-adjusted model, the values of effect sizes were in the same direction.

Based on the results of receiver operator characteristic (ROC) analyses, the optimal cut-off point of AIP for incident NAFLD was 0.00 (ROC 0.76 [95% CI 0.75–0.77], sensitivity 0.68, specificity 0.72, $p < 0.001$). Multivariate Cox regression indicated that participants with AIP values in the positive range (> 0) had two-fold increased odds of developing NAFLD compared with those with values in the negative range (≤ 0).

Stratified and interaction analyses

Stratified analyses will help us better observe trends in the association between AIP level and incident NAFLD in different populations. We used age, sex, BMI, SBP, DBP, FPG, TG, HDL, and TC as the stratification variables (**Figure 3**). We noted that only a small number of interactions were observed based on the priori specification (including BMI, blood pressure, and triglycerides; p values for interaction < 0.05). We found the stronger association between AIP level and incident NAFLD in participants with a healthy weight, normal blood pressure, and low triglycerides levels. In contrast, the weaker association between AIP level and incident NAFLD was detected in participants with high blood pressure and high triglycerides levels. The stratified analyses revealed that AIP was an independent predictor of NAFLD among participants with healthy metabolic state.

Discussion

Our novel results show that AIP level at baseline was independently associated with the risk of new-onset NAFLD in non-obese Chinese populations, and this association remained significantly even after adjusting covariates. The model-based effect sizes can be interpreted as every one-SD (0.28) of AIP level increasing is associated with increasing 52% in the incidence of NAFLD. To our knowledge, no previous studies have explored the association between AIP and new-onset NAFLD among non-obese participants.

AIP as an atherogenic index is a practical tool for assessing changes in the lipoprotein profile. Ampuero et al. found AIP level was positively associated the presence of adverse metabolic factors[15]. The relationship between TG and HDL-c in this simple ratio theoretically reflects the balance between risk and protective lipoprotein forces[5]. Studies indicated a positive association between AIP and cholesterol esterification rates, lipoprotein particle size, and remnant lipoproteinemia[6, 16]. Compared with either

plasma TG or HDL-C levels, AIP provided a more accurate predictive abilities in incident NAFLD, it appears that simultaneous use of these variables (and their mutual relationship) provides more accurate information[17].

Recently, Wang et al. conducted a cross-sectional study including 538 obese participants[18]. They demonstrated AIP was strongly correlated with NAFLD in those participants. To further address the question of whether the abnormalities in AIP level precede incident NAFLD or whether incident NAFLD leads to elevated AIP level, we conducted the longitudinal study. Our study indicated AIP level at baseline could predict incident NAFLD. In addition, we found that the optimal cut-off point of AIP for incident NAFLD was 0.00. A practical advantage of using AIP is that individuals with low risk for NAFLD have AIP values in the negative (“safe”) range, those with higher risk for NAFLD have AIP values in the positive (“danger”) range.

The clinical value of our study is as follows (1) To our knowledge, it is the first time to observe AIP is a strong predictor of incident NAFLD in Chinese non-obese individuals. Through subgroup analysis, our results revealed the need for early emphasis on lifestyle modification in individuals with positive (“danger”) range of AIP, even those with normal values of BMI, blood pressure, plasma lipids, or fasting plasma glucose; (2) Considering the measurement of TG and HDL-c is convenient and standardized in routine clinical practice, AIP may be clinically useful in identifying people at higher risk of developing NAFLD. These findings of our study may help to build a useful predictive model for incident NAFLD.

Our study has some strengths: (1) Compared with previous studies, the sample size of our study is relatively large; (2) We used strict statistical adjustment including Generalized additive model, penalized spline method, Cox regression, PSM, multiple imputation, and sensitivity analysis to minimize residual confounders. We handled the target independent variable as both continuous variable and categorical variable. Such an approach can reduce the contingency in the data analysis and enhance the robustness of results; (3) We did a subgroup analysis to explore the effect of AIP on incident NAFLD in different populations. Our findings provide evidence for early stage lifestyle intervention in individuals with positive (“danger”) AIP values, even those with metabolically healthy.

There are several limitations to our study. First, some participants missed clinical data. However, to minimize bias that might occur if individuals with missing data were excluded from multivariate analyses, we performed multiple imputations and then compared the results of complete data cohort with the results multiple imputation cohort. We found that the results from the two cohorts were similar (Supplementary Table 1). Second, NAFLD was diagnosed by a non-invasive test (ultrasound). liver biopsy

remains the 'gold standard' for diagnosing NAFLD. However, in population-based studies, liver biopsy is logistically challenging and unethical in asymptomatic participants who undergone routine health checkups.

Conclusion

It is a large longitudinal study to investigate whether AIP is an independent predictor of incident NAFLD in non-obese Chinese participants. Our result indicated that individuals with elevated AIP levels at baseline had increased risk for NAFLD, even those with metabolically healthy.

References

1. Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-Tetri BA, Rinella ME: **Nonalcoholic fatty liver disease**. *Nature reviews Disease primers* 2015, **1**:15080.
2. Clark JM: **The epidemiology of nonalcoholic fatty liver disease in adults**. *Journal of clinical gastroenterology* 2006, **40 Suppl 1**:S5-10.
3. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A: **Clinical epidemiology and disease burden of nonalcoholic fatty liver disease**. *World journal of gastroenterology* 2017, **23**(47):8263-8276.
4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M: **Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes**. *Hepatology (Baltimore, Md)* 2016, **64**(1):73-84.
5. Dobiasova M: **Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications**. *Clinical chemistry* 2004, **50**(7):1113-1115.
6. Dobiasova M, Frohlich J: **The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL))**. *Clinical biochemistry* 2001, **34**(7):583-588.
7. Kalelioglu T, Genc A, Karamustafalioglu N, Emul M: **Assessment of cardiovascular risk via atherogenic indices in patients with bipolar disorder manic episode and alterations with treatment**. *Diabetes & metabolic syndrome* 2017, **11 Suppl 1**:S473-s475.
8. Onat A, Can G, Kaya H, Hergenc G: **"Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events**. *Journal of clinical lipidology* 2010, **4**(2):89-98.
9. Zhu XW, Deng FY, Lei SF: **Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus**. *Primary care diabetes* 2015, **9**(1):60-67.

10. Edwards MK, Blaha MJ, Loprinzi PD: **Atherogenic Index of Plasma and Triglyceride/High-Density Lipoprotein Cholesterol Ratio Predict Mortality Risk Better Than Individual Cholesterol Risk Factors, Among an Older Adult Population.** *Mayo Clinic proceedings* 2017, **92**(4):680-681.
11. Kim D, Kim WR: **Nonobese Fatty Liver Disease.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2017, **15**(4):474-485.
12. Sun DQ, Wu SJ, Liu WY, Wang LR, Chen YR, Zhang DC, Braddock M, Shi KQ, Song D, Zheng MH: **Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study.** 2016, **6**(12):e013781.
13. **Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.** *Lancet (London, England)* 2004, **363**(9403):157-163.
14. Zeng MD, Fan JG, Lu LG, Li YM, Chen CW, Wang BY, Mao YM: **Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases.** *Journal of digestive diseases* 2008, **9**(2):108-112.
15. Ampuero J, Aller R: **The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.** 2018, **48**(11-12):1260-1270.
16. Dobiasova M, Frohlich J, Sedova M, Cheung MC, Brown BG: **Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.** *Journal of lipid research* 2011, **52**(3):566-571.
17. Niriella MA, Pathmeswaran A, De Silva ST, Kasturiratna A, Perera R, Subasinghe CE, Kodisinghe K, Piyaratna C, Rishikesawan V, Dassanayaka AS *et al.*: **Incidence and risk factors for non-alcoholic fatty liver disease: A 7-year follow-up study among urban, adult Sri Lankans.** *Liver international : official journal of the International Association for the Study of the Liver* 2017, **37**(11):1715-1722.
18. Wang Q, Zheng D, Liu J, Fang L, Li Q: **Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: a cross-sectional study.** *Lipids in health and disease* 2018, **17**(1):284.

Abbreviations

AIP: atherogenic index of plasma; ALT: alanine transaminase; AST: aspartate transaminase; BMI: body mass index; BUN: blood urea nitrogen; CI: confidence interval; DBP: diastolic blood pressure; FPG: fasting plasma glucose; GGT γ -glutamyl transpeptidase; HDL: high density lipoprotein cholesterol; HR: hazard ratio; LDL: low density lipoprotein; NAFLD: nonalcoholic fatty liver disease; SBP: systolic blood pressure; SD: standard deviation; TC: total cholesterol; TG: triglyceride; UA: uric acid.

Declarations

Competing interest statement

All authors: no conflicts.

Funding

No funding.

Acknowledgements

None

Authors’ contributions

Ye HJ and He XX designed the study. Ye HJ, Chen XY and Huang ZM extracted and analyzed data. Ye HJ and He XX prepared tables and figures. All authors reviewed the results, interpreted data, and wrote the manuscript.

All authors approved the final version of the manuscript.

Ethics approval and consent to participate

This study was the second analysis of existing data. The data was anonymous, so no informed consent is required.

Consent for publication

Not applicable.

Availability of data and materials

Data can be downloaded from the ‘DATADRYAD’ database (www.datadryad.org).

Tables

Table 1 Baseline Characteristics of Study Participants stratified by AIP quartiles (N =16 173).

Characteristics	Q1	Q2	Q3	Q4	P value
	-0.89 to -0.31	-0.30 to -0.14	-0.13 to 0.06	0.07- 1.83	
No. of participants	3841	4014	4174	4144	
Age (years)	42.4 ± 14.7	42.6 ± 14.8	43.5 ± 15.0	44.3 ± 15.3	<0.001
Male, N (%)	1844 (48.0%)	2037 (50.7%)	2228 (53.4%)	2374 (57.3%)	<0.001
BMI (kg/m ²)	20.5 ± 1.9	21.0 ± 2.0	21.6 ± 2.0	22.4 ± 1.8	<0.001
SBP (mmHg)	115.5 ± 15.7	118.7 ± 16.4	122.0 ± 16.5	126.1 ± 16.4	<0.001
DBP (mmHg)	69.7 ± 9.6	71.6 ± 9.9	73.3 ± 10.2	76.4 ± 10.5	<0.001
ALT (IU/L)	14.0 (11.0- 18.0)	15.0 (12.0- 21.0)	17.0 (12.0- 23.0)	20.0 (15.0- 28.0)	<0.001
AST (IU/L)	20.0 (17.0- 24.0)	21.0 (18.0- 25.0)	21.0 (18.0- 25.0)	23.0 (20.0- 27.0)	<0.001
GGT (IU/L)	17.0 (14.0- 22.0)	19.0 (15.0- 26.0)	22.0 (17.0- 31.0)	29.0 (21.0- 44.0)	<0.001
Albumin (mmol/L)	44.3 ± 2.7	44.3 ± 2.8	44.4 ± 2.8	44.7 ± 2.7	<0.001
Bilirubin (mmol/L)	12.0 ± 4.9	12.2 ± 4.8	12.3 ± 4.9	12.2 ± 5.2	0.213
BUN (mmol/L)	4.5 ± 1.3	4.6 ± 1.4	4.7 ± 1.5	4.6 ± 1.4	<0.001
Creatinine (mmol/L)	71.3 ± 15.7	76.1 ± 21.7	81.0 ± 31.5	84.9 ± 28.1	<0.001
Uric acid (mmol/L)	237.2 ± 70.1	260.9 ± 77.9	289.4 ± 80.7	327.9 ± 86.0	<0.001
Fasting glucose (mmol/L)	5.0 ± 0.6	5.1 ± 0.7	5.2 ± 0.8	5.3 ± 0.9	<0.001
TG (mmol/L)	0.7 ± 0.1	0.9 ± 0.2	1.3 ± 0.3	2.3 ± 1.3	<0.001
TC (mmol/L)	4.6 ± 0.7	4.6 ± 0.7	4.6 ± 0.7	4.7 ± 0.8	<0.001
HDL-C (mmol/L)	1.8 ± 0.3	1.6 ± 0.3	1.4 ± 0.2	1.1 ± 0.2	<0.001
LDL-C (mmol/L)	2.1 ± 0.5	2.2 ± 0.5	2.3 ± 0.4	2.4 ± 0.4	<0.001
NAFLD, N (%)	109 (2.8%)	305 (7.6%)	544 (13.0%)	1364 (32.9%)	<0.001

Note: AIP atherogenic index of plasma, ALT alanine aminotransferase, AST aspartate transaminase, BMI body mass index, BUN blood urea nitrogen, GGT γ-glutamyl transpeptidase, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NAFLD nonalcoholic fatty liver disease, SBP systolic pressure, DBP Diastole pressure, TG triglyceride, TC total cholesterol.

Table 2 The results of univariate Cox regression analysis.

	Statistics	Effect size (HR 95%CI)	P value
Age (years)	43.2+15.0	1.01 (1.00, 1.01)	<0.001
Male, N (%)	8483 (52.5%)	1.18 (1.09, 1.28)	<0.001
BMI (kg/m)	21.4+2.0	1.82 (1.77, 1.87)	<0.001
SBP (mmHg)	120.7+16.7	1.02 (1.02, 1.02)	<0.001
DBP (mmHg)	72.8+10.4	1.05 (1.04, 1.05)	<0.001
ALT (IU/L)	16.0 (12.0- 23.0)	1.01 (1.01, 1.01)	<0.001
AST (IU/L)	21.0 (18.0- 25.0)	1.01 (1.01, 1.01)	<0.001
GGT (IU/L)	22.0 (16.0- 31.0)	1.01 (1.01, 1.01)	<0.001
Albumin (mmol/L)	44.4+2.7	1.01 (0.99, 1.02)	0.477
Bilirubin (mmol/L)	12.2+5.0	1.01 (0.99, 1.02)	0.706
BUN (mmol/L)	4.6+1.4	0.93 (0.90, 0.96)	<0.001
Creatinine (mmol/L)	78.5+25.7	1.00 (1.00, 1.01)	<0.001
Uric acid (mmol/L)	279.8+85.9	1.01 (1.00, 1.01)	<0.001
Fasting glucose (mmol/L)	5.1+0.8	1.30 (1.27, 1.33)	<0.001
TG (mmol/L)	1.3+0.9	1.20 (1.19, 1.22)	<0.001
TC (mmol/L)	4.6+0.7	1.30 (1.24, 1.37)	<0.001
HDL-C (mmol/L)	1.5+0.4	0.28 (0.25, 0.32)	<0.001
LDL-C (mmol/L)	2.3+0.5	1.94 (1.77, 2.14)	<0.001

Note: HR hazard ratio, CI confidence interval, ALT alanine aminotransferase, AST aspartate transaminase, BMI body mass index, BUN blood urea nitrogen, GGT γ -glutamyl transpeptidase, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NAFLD nonalcoholic fatty liver disease, SBP systolic pressure, DBP Diastole pressure, TG triglyceride, TC total cholesterol.

Table 3 Effect Modification of AIP on incident of NAFLD.

		Unadjusted Model		Model I		Model II	
		HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
AIP	Per	1.97 (1.91, 2.04)	<0.001	1.58 (1.52, 1.63)	<0.001	1.52 (1.43, 1.60)	<0.001
SD*							
Categories							
AIP Q1	Ref			Ref		Ref	
AIP Q2	2.69 (2.16, 3.34)	<0.001		2.06 (1.65, 2.56)	<0.001	2.34 (1.73, 3.15)	<0.001
AIP Q3	4.49 (3.65, 5.51)	<0.001		2.79 (2.27, 3.43)	<0.001	2.77 (2.08, 3.70)	<0.001
AIP Q4	11.87 (9.76, 14.43)	<0.001		5.26 (4.31, 6.42)	<0.001	4.51 (3.40, 5.97)	<0.001
P for trend	<0.001			<0.001		<0.001	
Categories							
AIP Q1-Q3	Ref			Ref	Ref	Ref	
AIP Q4	4.25 (3.92, 4.62)	<0.001		2.45 (2.24, 2.66)	<0.001	1.92 (1.72, 2.15)	<0.001
Categories							
AIP $\leq$ 0	Ref			Ref		Ref	
AIP > 0	4.15 (3.81, 4.52)	<0.001		2.42 (2.21, 2.64)	<0.001	1.94 (1.73, 2.18)	<0.001

Model I adjusted for age, sex, BMI, SBP, and DBP.

Model II adjusted for Model I plus ALT, AST, GGT, albumin, bilirubin, BUN, creatinine, uric acid, fasting glucose, TC, LDL.

*Mean API was -0.10 (SD 0.28)

HR hazard ratio, CI confidence interval, SD standard deviation, Ref reference.

Table 4 Characteristics of participants after Propensity-Score Matching

	No NAFLD (n=1365)	NAFLD (n=1365)	P value
Age (years)	46.04 ± 15.76	46.01 ± 15.35	0.961
Male, N (%)	788 (57.7)	781 (57.2)	0.816
BMI (kg/m ²)	23.09 ± 1.34	23.08 ± 1.35	0.919
SBP (mmHg)	129.02 ± 17.47	128.73 ± 16.28	0.647
DBP (mmHg)	77.41 ± 10.62	77.52 ± 9.87	0.790
ALT (IU/L)	24.02 ± 30.32	24.79 ± 14.18	0.393
AST (IU/L)	24.38 ± 14.62	24.63 ± 8.60	0.595
GGT (IU/L)	38.04 ± 40.55	39.89 ± 34.68	0.200
Albumin (mmol/L)	44.55 ± 2.70	44.57 ± 2.78	0.828
Bilirubin (mmol/L)	12.49 ± 5.60	12.51 ± 5.01	0.925
BUN (mmol/L)	4.70 ± 1.37	4.66 ± 1.38	0.532
Creatinine (mmol/L)	88.16 ± 18.59	88.23 ± 20.95	0.923
Uric acid (mmol/L)	322.11 ± 85.79	323.64 ± 82.69	0.636
Fasting glucose (mmol/L)	5.46 ± 1.19	5.47 ± 0.93	0.835
TC (mmol/L)	4.72 ± 0.72	4.75 ± 0.75	0.300
LDL-C (mmol/L)	2.38 ± 0.45	2.39 ± 0.47	0.547
Year of follow up	1.93 (1.12-2.07)	1.93 (1.05-2.13)	0.504
Atherogenic index of plasma	-0.01 ± 0.26	0.12 ± 0.28	<0.001
(log ₁₀ (TG/HDL-C))	-0.03 (-0.20 - 0.15)	0.11 (-0.07 - 0.29)	

Note: ALT alanine aminotransferase, AST aspartate transaminase, BMI body mass index, BUN blood urea nitrogen, GGT γ-glutamyl transpeptidase, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NAFLD nonalcoholic fatty liver disease, SBP systolic pressure, DBP Diastole pressure, TG triglyceride, TC total cholesterol.

Supplementary Table 1 Comparing the results of multivariate regression between complete case data and multiple imputation data.

	Complete case		Multiple imputation	
	HR (95% CI)	P value	HR (95% CI)	P value
AIP, Per SD increase	1.52 (1.43, 1.60)	<0.001	1.51 (1.48, 1.54)	<0.001
Categories				
AIP Q1	Ref		Ref	
AIP Q2	2.34 (1.73, 3.15)	<0.001	1.85 (1.67, 2.04)	<0.001
AIP Q3	2.77 (2.08, 3.70)	<0.001	2.43 (2.21, 2.66)	<0.001
AIP Q4	4.51 (3.40, 5.97)	<0.001	4.20 (3.84, 4.60)	<0.001
P for trend	<0.001		<0.001	
Categories				
AIP Q1-Q3	Ref		Ref	
AIP Q4	1.92 (1.72, 2.15)	<0.001	2.12 (2.04, 2.21)	<0.001
Categories				
AIP ≤ 0	Ref		Ref	
AIP > 0	1.94 (1.73, 2.18)	<0.001	2.08 (2.00, 2.17)	<0.001

Adjusted for age, sex, BMI, SBP, DBP, ALT, AST, GGT, albumin, bilirubin, BUN, creatinine, uric acid, fasting glucose, TC, LDL.

HR hazard ratio, CI confidence interval, SD standard deviation, Ref reference.

Figures

Figure 1

Kaplan-Meier curves stratified by AIP quartiles.

Figure 2

The relationship between AIP and incident NAFLD. (A) Unadjusted; (B) Adjusted for age, sex, BMI, SBP, DBP, ALT, AST, GGT, albumin, bilirubin, BUN, creatinine, uric acid, fasting glucose, TC, LDL.

Figure 3

The effect size of AIP on incident NAFLD in different subgroups. Adjusted for age, sex, BMI, SBP, DBP, ALT, AST, GGT, albumin, bilirubin, BUN, creatinine, uric acid, fasting glucose, TC, LDL. Not adjusted for the stratification variable.